Vasopressin in cirrhosis and sepsis: Physiology and clinical implications

Minerva Anestesiologica

Volumn 81, Issue 12, 2015, Pages 1377-1383

  Wagener, G ^a   Bakker, J ^a,b  

^a Columbia University New York ^*  (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Liver cirrhosis; Sepsis; Vasopressins

Indexed keywords

ARGIPRESSIN; VASOPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

BLOOD VESSEL TONE; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; PHYSIOLOGY; REVIEW; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME; VASODILATATION; DRUG EFFECTS; LIVER CIRCULATION; SHOCK, SEPTIC;

ARGININE VASOPRESSIN; HUMANS; LIVER CIRCULATION; LIVER CIRRHOSIS; SEPSIS; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84950317192     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96: II-286-90.
2. Malay MB, Ashton RC, Jr., Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. The Journal of trauma 1999; 47: 699-703.
3. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-87.
4. Saito T, Takanashi M, Gallagher E, Fuse A, Suzaki S, Inagaki O, et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: Hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med 1995; 21: 204-10.
5. Tagawa T, Imaizumi T, Endo T, Shiramoto M, Hirooka Y, Ando S, et al. Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels. J Clin Invest 1993; 92: 1483-90.
6. Tagawa T, Imaizumi T, Shiramoto M, Endo T, Hironaga K, Takeshita A. V2 receptor-mediated vasodilation in healthy humans. J Cardiovasc Pharmacol 1995; 25: 387-92.
7. Peters J, Schlaghecke R, Thouet H, Arndt JO. Endogenous vasopressin supports blood pressure and prevents severe hypotension during epidural anesthesia in conscious dogs. Anesthesiology 1990; 73: 694-702.
8. Fernandez N, Garcia JL, Garcia-Villalon AL, Monge L, Gomez B, Dieguez G. Coronary vasoconstriction produced by vasopressin in anesthetized goats. Role of vasopressin V1 and V2 receptors and nitric oxide. Eur J Pharmacol 1998; 342: 225-33.
9. Schweitzer EJ, Kerr JC, Swan KG. Clinical use of vasopressin in the management of bleeding esophageal varices. Am Surg 1982; 48: 558-62.
10. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-5.
11. O'Brien AJ, Thakur G, Buckley JF, Singer M, Clapp LH. The pore-forming subunit of the K(ATP) channel is an important molecular target for LPS-induced vascular hyporeactivity in vitro. Br J Pharmacol 2005; 144: 367-75.
12. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-95.
13. Dubois MJ, De Backer D, Creteur J, Anane S, Vincent JL. Effect of vasopressin on sublingual microcirculation in a patient with distributive shock. Intensive Care Med 2003; 29: 1020-3.
14. Morelli A, Donati A, Ertmer C, Rehberg S, Orecchioni A, Di Russo A, et al. Short-term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock. Intensive Care Med 2011; 37: 963-9.
15. Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, et al. Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock. Crit Care 2011; 15: R217.
16. Boerma EC, van der Voort PH, Ince C. Sublingual microcirculatory flow is impaired by the vasopressin-analogue terlipressin in a patient with catecholamine-resistant septic shock. Acta Anaesthesiol Scand 2005; 49: 1387-90.
17. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96: 576-82.
18. Luckner G, Dunser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33: 2659-66.
19. Mehta S, Granton J, Gordon AC, Cook DJ, Lapinsky S, Newton G, et al., Vasopressin and Septic Shock Trial (VASST) Investigators. Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Crit Care 2013; 17: R117.
20. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
21. Frances R, Benlloch S, Zapater P, González JM, Lozano B, Muñoz C, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39: 484-91.
22. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005; 42: 195-201.
23. Wagener G, Kovalevskaya G, Minhaz M, Mattis F, Emond JC, Landry DW. Vasopressin deficiency and vasodilatory state in end-stage liver disease. J Cardiothorac Vasc Anesth 2011; 25: 665-70.
24. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmerón JM, Jiménez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
25. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
26. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.
27. Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2012; 9: CD005162.
28. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
29. Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, et al. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. J Int Med Res 2013; 41: 835-47.
30. Rehberg S, Ertmer C, Lange M, Morelli A, Whorton E, Dünser M, et al. Role of selective V2-receptor-antagonism in septic shock: A randomized, controlled, experimental study. Crit Care 2010; 14: R200.
31. Landry DW, Oliver JA. Increased complexity of vasopressin's vascular actions. Crit Care 2010; 14: 1011.
32. Wagener G, Gubitosa G, Renz J, Kinkhabwala M, Brentjens T, Guarrera JV, et al. Vasopressin decreases portal vein pressure and flow in the native liver during liver transplantation. Liver Transpl 2008; 14: 1664-70.
33. Asakura T, Ohkohchi N, Orii T, Koyamada N, Tsukamoto S, Sato M, et al. Portal vein pressure is the key for successful liver transplantation of an extremely small graft in the pig model. Transpl Int 2003; 16: 376-82.
34. Wang HS, Enomoto Y, Usuda M, Miyagi S, Asakura T, Masuoka H, Excessive portal flow causes graft nonfunction in small size liver transplantation: An experimental study in pigs. Transplant proc 2005; 37: 407-8.